Kari Martin, MD
Dermatology · Columbia, MONPI 1083811335
Payments from drug & device makers
What this record shows
5 manufacturers reported payments, led by Johnson & Johnson at 53.0% of the total. That places this record below the midpoint for dermatology clinicians in MO, where the typical reported total is $3,173.
Across 6 payments — averaging $28.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$89
- AbbVie$34
- Highridge Medical LLC$17
- Pharming Healthcare, Inc.$15
- Krystal Biotech Inc$13
Across 8 payments — averaging $4425.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$33K
- Eli Lilly Export S.A. Puerto Rico Branch$2K
What the payments were for
- Food & beverage$7947%
- Education$8953%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $89 |
| AbbVie | 2 | $34 |
| Highridge Medical LLC | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $15 |
| Krystal Biotech Inc | 1 | $13 |
How this compares
$168 in reported general payments places this provider in the 5th percentile of 263 dermatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 15 | $302,817 |
| Humira(Cf) PenAdalimumab | 15 | $177,917 |
| Dupixent PenDupilumab | 19 | $147,966 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $111,701 |
| Taltz SyringeIxekizumab | 12 | $81,657 |
| HyftorSirolimus | 13 | $43,815 |
| Acitretin | 19 | $4,166 |
| Azelaic Acid | 13 | $1,843 |
| Clobetasol Propionate | 40 | $1,730 |
| Tacrolimus | 15 | $1,468 |
| Clindamycin Phosphate | 22 | $1,204 |
| Minocycline Hcl | 16 | $1,122 |
| Tretinoin | 14 | $939 |
| Doxycycline Hyclate | 33 | $859 |
| Hydroxychloroquine Sulfate | 16 | $645 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Columbia
- Kaitlin SchiavoColumbia$16K
- Kimberly CayceColumbia$10K
- Justin WelchColumbia$10K
- Brian KimSaint Louis$861K
- Elaine SiegfriedSaint Louis$856K
- Craig LeonardiSaint Louis$569K
- Jonathan CleaverKirksville$483K
- Mary GeorgeSaint Louis$400K
- David CleaverKirksville$371K
- Christy RaineyBranson$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.